WO2008010428A1 - Agent immunomodulateur - Google Patents
Agent immunomodulateur Download PDFInfo
- Publication number
- WO2008010428A1 WO2008010428A1 PCT/JP2007/063582 JP2007063582W WO2008010428A1 WO 2008010428 A1 WO2008010428 A1 WO 2008010428A1 JP 2007063582 W JP2007063582 W JP 2007063582W WO 2008010428 A1 WO2008010428 A1 WO 2008010428A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ratatosucrose
- weeks
- parts
- immunomodulator
- weight
- Prior art date
Links
- 239000002955 immunomodulating agent Substances 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 claims abstract description 25
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 12
- 239000004480 active ingredient Substances 0.000 claims abstract description 7
- 229940099472 immunoglobulin a Drugs 0.000 claims description 32
- 230000002584 immunomodulator Effects 0.000 claims description 20
- 229940121354 immunomodulator Drugs 0.000 claims description 20
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 18
- 229930006000 Sucrose Natural products 0.000 claims description 18
- 238000004519 manufacturing process Methods 0.000 claims description 18
- 239000005720 sucrose Substances 0.000 claims description 18
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 17
- 206010020751 Hypersensitivity Diseases 0.000 claims description 15
- 230000007815 allergy Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 230000036039 immunity Effects 0.000 claims description 13
- 208000026935 allergic disease Diseases 0.000 claims description 12
- 230000008944 intestinal immunity Effects 0.000 claims description 12
- 230000009885 systemic effect Effects 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 7
- 235000013305 food Nutrition 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 230000001629 suppression Effects 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 201000008937 atopic dermatitis Diseases 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 235000005911 diet Nutrition 0.000 abstract description 6
- FVVCFHXLWDDRHG-UPLOTWCNSA-N (2s,3r,4s,5r,6r)-2-[(2r,3s,4r,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 FVVCFHXLWDDRHG-UPLOTWCNSA-N 0.000 abstract description 5
- 230000002411 adverse Effects 0.000 abstract 1
- 230000000378 dietary effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 description 40
- 238000012360 testing method Methods 0.000 description 31
- 239000000126 substance Substances 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 235000013402 health food Nutrition 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- 230000037406 food intake Effects 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 230000000172 allergic effect Effects 0.000 description 17
- 208000010668 atopic eczema Diseases 0.000 description 17
- 239000000427 antigen Substances 0.000 description 16
- 108091007433 antigens Proteins 0.000 description 16
- 102000036639 antigens Human genes 0.000 description 16
- 150000001720 carbohydrates Chemical class 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 235000000346 sugar Nutrition 0.000 description 15
- 241000218645 Cedrus Species 0.000 description 14
- 108010058846 Ovalbumin Proteins 0.000 description 14
- 206010070834 Sensitisation Diseases 0.000 description 14
- 229940027941 immunoglobulin g Drugs 0.000 description 14
- 229940092253 ovalbumin Drugs 0.000 description 14
- 230000008313 sensitization Effects 0.000 description 14
- 230000036737 immune function Effects 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 230000000968 intestinal effect Effects 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 10
- 210000001986 peyer's patch Anatomy 0.000 description 10
- 241000218691 Cupressaceae Species 0.000 description 9
- 230000009471 action Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000000796 flavoring agent Substances 0.000 description 8
- 235000019634 flavors Nutrition 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 230000003247 decreasing effect Effects 0.000 description 7
- 235000013399 edible fruits Nutrition 0.000 description 7
- 230000028993 immune response Effects 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- 241000287828 Gallus gallus Species 0.000 description 6
- 206010048908 Seasonal allergy Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 235000013330 chicken meat Nutrition 0.000 description 6
- 229940076144 interleukin-10 Drugs 0.000 description 6
- 239000003504 photosensitizing agent Substances 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- 102000004388 Interleukin-4 Human genes 0.000 description 5
- 108090000978 Interleukin-4 Proteins 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229940028885 interleukin-4 Drugs 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 239000008267 milk Substances 0.000 description 5
- 210000004080 milk Anatomy 0.000 description 5
- 229940109850 royal jelly Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 4
- 240000005109 Cryptomeria japonica Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 108010074328 Interferon-gamma Proteins 0.000 description 4
- 102000004889 Interleukin-6 Human genes 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 206010048685 Oral infection Diseases 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 210000004534 cecum Anatomy 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 229940100601 interleukin-6 Drugs 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- -1 ratatopherin Proteins 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 239000006188 syrup Substances 0.000 description 4
- 235000020357 syrup Nutrition 0.000 description 4
- 235000021195 test diet Nutrition 0.000 description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 235000019156 vitamin B Nutrition 0.000 description 4
- 239000011720 vitamin B Substances 0.000 description 4
- 235000013618 yogurt Nutrition 0.000 description 4
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 3
- 102100037850 Interferon gamma Human genes 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 102000000743 Interleukin-5 Human genes 0.000 description 3
- 108010002616 Interleukin-5 Proteins 0.000 description 3
- 241000935974 Paralichthys dentatus Species 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 239000013566 allergen Substances 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229940025878 hesperidin Drugs 0.000 description 3
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 3
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 229940100602 interleukin-5 Drugs 0.000 description 3
- 230000003871 intestinal function Effects 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 238000013077 scoring method Methods 0.000 description 3
- 210000004989 spleen cell Anatomy 0.000 description 3
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical group CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000219495 Betulaceae Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016952 Food poisoning Diseases 0.000 description 2
- 208000019331 Foodborne disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010068370 Glutens Proteins 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 206010039094 Rhinitis perennial Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 230000006353 environmental stress Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000021312 gluten Nutrition 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 230000004957 immunoregulator effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000017448 oviposition Effects 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000009342 ragweed pollen Substances 0.000 description 2
- 210000003289 regulatory T cell Anatomy 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000004988 splenocyte Anatomy 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-CBPJZXOFSA-N 2-amino-2-deoxy-D-mannopyranose Chemical compound N[C@@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-CBPJZXOFSA-N 0.000 description 1
- QWJSAWXRUVVRLH-LREBCSMRSA-M 2-hydroxyethyl(trimethyl)azanium;(2r,3r)-2,3,4-trihydroxy-4-oxobutanoate Chemical compound C[N+](C)(C)CCO.OC(=O)[C@H](O)[C@@H](O)C([O-])=O QWJSAWXRUVVRLH-LREBCSMRSA-M 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 244000298697 Actinidia deliciosa Species 0.000 description 1
- 235000009436 Actinidia deliciosa Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 241000224489 Amoeba Species 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000252983 Caecum Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 244000018436 Coriandrum sativum Species 0.000 description 1
- 235000002787 Coriandrum sativum Nutrition 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000223935 Cryptosporidium Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 108010010256 Dietary Proteins Proteins 0.000 description 1
- 102000015781 Dietary Proteins Human genes 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000007056 Dioscorea composita Nutrition 0.000 description 1
- 235000009723 Dioscorea convolvulacea Nutrition 0.000 description 1
- 235000005362 Dioscorea floribunda Nutrition 0.000 description 1
- 235000004868 Dioscorea macrostachya Nutrition 0.000 description 1
- 235000005361 Dioscorea nummularia Nutrition 0.000 description 1
- 235000005360 Dioscorea spiculiflora Nutrition 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241001333951 Escherichia coli O157 Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 241000242711 Fasciola hepatica Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 241001062009 Indigofera Species 0.000 description 1
- 235000000177 Indigofera tinctoria Nutrition 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 235000006350 Ipomoea batatas var. batatas Nutrition 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- MLSJBGYKDYSOAE-DCWMUDTNSA-N L-Ascorbic acid-2-glucoside Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1O MLSJBGYKDYSOAE-DCWMUDTNSA-N 0.000 description 1
- 239000002211 L-ascorbic acid Substances 0.000 description 1
- 235000000069 L-ascorbic acid Nutrition 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000220225 Malus Species 0.000 description 1
- 235000011430 Malus pumila Nutrition 0.000 description 1
- 235000015103 Malus silvestris Nutrition 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000003250 Mixed connective tissue disease Diseases 0.000 description 1
- 240000005561 Musa balbisiana Species 0.000 description 1
- 235000018290 Musa x paradisiaca Nutrition 0.000 description 1
- 235000004347 Perilla Nutrition 0.000 description 1
- 244000124853 Perilla frutescens Species 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 235000019779 Rapeseed Meal Nutrition 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- 241000276699 Seriola Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 241000121220 Tricholoma matsutake Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000607272 Vibrio parahaemolyticus Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000001195 anabolic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical group COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 235000004879 dioscorea Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000006275 fascioliasis Diseases 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000005745 host immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229940097275 indigo Drugs 0.000 description 1
- COHYTHOBJLSHDF-UHFFFAOYSA-N indigo powder Natural products N1C2=CC=CC=C2C(=O)C1=C1C(=O)C2=CC=CC=C2N1 COHYTHOBJLSHDF-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229910000358 iron sulfate Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 238000004898 kneading Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 208000019180 nutritional disease Diseases 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000013573 pollen allergen Substances 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 235000008476 powdered milk Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 1
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 1
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 239000004456 rapeseed meal Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229940029079 rose petal extract Drugs 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 201000004409 schistosomiasis Diseases 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000006098 transglycosylation Effects 0.000 description 1
- 238000005918 transglycosylation reaction Methods 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
- 235000008939 whole milk Nutrition 0.000 description 1
- 235000008924 yoghurt drink Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/30—Artificial sweetening agents
- A23L27/33—Artificial sweetening agents containing sugars or derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to immunomodulation, and in particular, to an immunomodulator comprising ratatosucrose and an immunomodulation method using ratatosucrose.
- ⁇ -D-galactosinole (1, 4) -a-D-gnolecosinole (1, 2) - ⁇ -D-furatatoside, ie ratatosucrose is described in, for example, JP-A-3-27285.
- a solution containing sucrose and ratatose is added to the 13-flatatofurano derived from microorganisms.
- ratatosucrose has been shown to be resistant to digestion, bifidobacteria growth promotion, hard caries, and moisturizing, and is used in a wide range of applications such as food, cosmetics, and pharmaceuticals.
- the immunoregulatory effect of ratatosucrose is not known.
- an object of the present invention is to provide an immunomodulator and an immunomodulation method that can be continuously ingested in daily eating habits and do not have a side effect.
- ratatosucrose has obtained a novel finding that, when taken orally, it promotes secretion of IgA in the intestine via intestinal immune tissues such as Peyer's patch cells.
- ratatosucrose has been found to suppress the production of IgE, which is enhanced by immunizing allergens with alum adjuvant.
- a composition containing ratatosucrose enhances intestinal immunity and suppresses systemic immunity such as allergies by ingestion, and the present invention has been completed.
- the present invention solves the above-mentioned problems by providing an immunomodulator comprising ratatosucrose as an active ingredient and an animal immunomodulation method characterized by orally ingesting ratatosucrose. Is.
- the present invention since immunomodulation can be easily performed, it is effective for the prevention or treatment of oral infections, allergies, autoimmune diseases and the like.
- the immunomodulator of the present invention can be continuously taken in a daily diet, and there is no worry about side effects.
- FIG. 1 is a graph showing changes over time in clinical score of nose caused by hay fever.
- FIG. 2 is a graph showing changes over time in scores of clinical symptoms of eyes caused by hay fever.
- FIG. 3 is a diagram showing the change over time in the score of the degree of difficulty in daily life due to hay fever.
- the immunomodulator of the present invention contains ratatosucrose as an active ingredient.
- ratatosucrose As the form of ratatosucrose, syrup, honey-containing crystal powder, water-containing crystal, amorphous solid and the like can be appropriately selected as long as the effects of the present invention are not impaired.
- Commercially available products are also available, such as Hayashibara Shoji Co., Ltd. (trade names such as ⁇ Fruit Oligo 550 '' and ⁇ Fruit Oligo 700 '') and Shimizu Minato Sugar Co., Ltd. (trade name ⁇ LS-90P '').
- Ratatosucrose-containing carbohydrates sold under (1) may be used.
- the content of ratatosucrose in the immunomodulator of the present invention is usually 1 to 100% (wZw), preferably 10 to 10% per solid, as long as it is ingested by animals including humans and exhibits an immunomodulatory effect. 100% (w / w), more preferably 20 to 100% (wZw).
- the immunoregulatory effect referred to in the present invention includes two types of immunity: an action that enhances the secretion of IgA in intestinal immunity and an action that controls an excessive immune response in systemic immunity. It means a regulating action.
- the former activates intestinal immune tissues such as Peyer's patch cells, and in the intestinal tract, IgA, or a site force-in that promotes production of IgA, such as interleukin 6 (IL-6) or It is exerted by promoting the production of one-third of transforming dullose factor (TGF), the latter being a regulatory T cell against systemic immunocompetent cells such as spleen cells. It is exerted by suppressing excessive immune responses such as allergies and autoimmune diseases through activation of the liver.
- IL-6 interleukin 6
- TGF transforming dullose factor
- the immunomodulator of the present invention may be ratatosucrose alone, but in the form of food and drink, medicine, quasi-drug, health food, feed or feed containing ratatosucrose as an active ingredient. It can also be a composition.
- the composition includes components that are acceptable in the above forms, such as water, alcohol, starch, protein, dietary fiber, carbohydrate, lipid, vitamin, mineral, flavoring, coloring, sweetener, seasoning, spice, Stabilizers, antioxidants, preservatives, etc. can be added.
- proteins such as ratatopherin, casein, collagen, soy protein or their degradation products, flavonoids such as rutin, hesperidin, quercetin, isoflavone or their glycosides, calcium salts such as calcium lactate and calcium glycephosphate, vitamin A, vitamin B Vitamin B, Vitamin B, Vitamin B, Vitamin C Vitamins such as vitamin D and vitamin E, or derivatives thereof, sucrose, maltose, trenorose, manoletosinoretrenorose, -gerose, isomaleretose, -gerooligosaccharide, isomaltoligosaccharide, cyclic four Sugars, sugars such as cyclodextrins, amino sugars such as dalcosamine, galatatosamine, mannosamine, glycosaminodarlicans such as hyaluronic acid, chondroitin sulfate, heparan sulfate, sugar alcohols such as sorbitol
- the immunomodulator of the present invention enhances intestinal immunity by promoting secretion of IgA, viruses such as hepatitis A virus, poliovirus, rotavirus, cholera, shigella, typhoid fever.
- viruses such as hepatitis A virus, poliovirus, rotavirus, cholera, shigella, typhoid fever.
- the immunomodulator of the present invention suppresses the secretion of antigen-specific IgE and suppresses an excessive immune response to the specific antigen, and thus, for example, egg, milk, wheat, peanut, abalone, squid , How much, shrimp, orange, power, kiwifruit, beef, walnut, salmon, mackerel, soybean, chicken, banana, matsutake, peach, yam, apple, gelatin, etc., food allergies such as cedar pollen, cypress pollen , Pollinosis caused by cereals pollen, camphor pollen, alder pollen, alder pollen, birch pollen, ragweed pollen, ragweed pollen, mugwort pollen, canamdala pollen, pollen from other grasses For example, allergy due to house dust, metal, chemical substances, atopic dermatitis, allergic rhinitis, allergic Allergic diseases such as membrane inflammation, allergic gastroenteritis, asthma, urticaria, Crohn's disease,
- any method can be used as long as ratatosucrose can reach the intestine.
- Oral or tube routes are usually selected.
- Ratatosucrose as an active ingredient that should be appropriately determined in consideration of the method of administration or method of intake, the type of animal to be applied, etc., is usually 0.001 to 20 gZkg body weight per day. Preferably, it may be administered or ingested within the range of 0.01 to 15 gZkg body weight, more preferably 0.02 to lOgZkg body weight.
- the weight is less than 001 g / kg body weight, the desired effect will not be exerted, and if it exceeds 20 gZkg body weight, the effect will not be exerted.
- the maximum inactive dose of ratatosucrose is 0.6 to 0.8 gZkg body weight, so administration or ingestion exceeding this range causes diarrhea. It is possible to be careful.
- the immunomodulator of the present invention can be applied to all vertebrates having an immune system similar to that of humans, which is usually applied to humans.
- domestic animals such as horsetail, horse, pig, and hidge, pets such as dogs, cats, and monkeys, poultry such as chickens, ducks, and turkeys, and fish such as Thailand and yellowtails. It can be blended into feed and feed.
- Feeds and feeds containing lactosucrose can prevent infections such as viruses and bacteria against livestock and poultry whose immunity has been reduced due to environmental stress such as high and low temperatures. Symptoms can be alleviated, so that the physical strength of livestock and poultry can be prevented and the plants can grow efficiently. In addition, for example, it reduces the milking amount for dairy cows and prevents the fall of the egg-laying rate for chickens.
- test feed (ratatosucrose-containing saccharide content was also reduced cornstarch power) to a group of 5 mice with a ratatosucrose content of 5% (w / w).
- Ad libitum As a control, a mouse fed with a standard purified feed (AIN-93G) without ratatosucrose was prepared.
- AIN-93G standard purified feed
- fresh feces were collected from the mouse and ELIS A method using anti-IgA antibody (mouse IgA ELISA)
- the amount of IgA was measured with a Quantitation Kit (manufactured by BETHYL).
- the IgA amount was expressed in milligrams per wet mass of feces, and the average value of 5 mice was obtained.
- the results are shown in Table 1.
- the percentage values in parentheses in the table indicate relative values to the control in each week.
- mice reared with the control refined diet decreased the amount of IgA in the feces as the breeding period (weeks) progressed. This phenomenon was caused by feeding mice with clean purified feed and reducing the amount of antigen taken orally. It is thought that the tract immune function was lowered.
- the purified feed containing ratatosucrose was also clean, but in the mice raised with this, the amount of IgA in the feces was high throughout the breeding period. Therefore, ratatosucrose was found to have an action of activating the intestinal tract immune system and maintaining IgA secretion at a high level.
- mice bred for 4 weeks on a purified diet containing 5% (wZw) ratatosucrose or a control purified diet (AIN-93G) were sacrificed and the cecum was removed.
- the contents of the cecum were taken out of the cecum and the pH, mass, IgA amount and IgG amount were measured.
- the amount of antibody per gram of content was measured by the ELISA method using an anti-IgA antibody for the IgA amount, and by the ELISA method (mouse IgG ELISA Quantitation Kit, manufactured by BETHYL) using an anti-IgG antibody for the IgG amount. .
- the results are shown in Table 2.
- the percentage values in parentheses in the table indicate relative values to the control in each week.
- ratatosucrose lowered the pH of the caecum contents and significantly increased the amount of contents, so it increased the amount of organic acids and improved the intestinal environment. It was suggested to have. Ratatosucrose increased the secretion of IgA by about 10 times without affecting the amount of IgG.
- Tables 1 and 2 show that ratatosucrose has the effect of enhancing intestinal immunity! / Speak.
- ratatosucrose-containing sugar (trade name “LS-90P”, sold by Shimizu Minato Sugar Co., Ltd., 99.8% (w / w) containing ratatosucrose in terms of solids)
- a test feed with a ratatosucrose content of 2% (w / w) or 5% (w / w) (with a mass of ratatosucrose-containing carbohydrates and reduced corn starch power) was added to 5 animals per group. Mice were fed ad libitum. Further, as a control, a mouse fed with a standard purified feed (AI N-93G) containing no extra sucrose was prepared.
- Cells floating around the interface between the 45% (vZv) Barcol layer and the 75% (vZv) Percoll layer are collected, suspended in RPMI 1640 medium containing 10% FC S and 10 mM HEPES, and a cell concentration of 1 X 10 6 Zml were prepared. Inoculate 1 ml of each well into a 24-well microphone mouthplate, and then add 2 gZml of Concanapalin A (ConA) as a stimulator for T cells or 10 ⁇ gZml of lipoprotein as a stimulant for B cells and macrophage cells. Polysaccharide (LPS) was added and cultured at 37 ° C for 48 hours in a 5% (vZv) carbon dioxide atmosphere.
- ConA Concanapalin A
- LPS Polysaccharide
- Collect culture supernatant from each well and contain IgA, IgG, IFN-y, interleukin-4 (IL-4), IL-6, interleukin-10 (IL-10) and TGF- ⁇ .
- ELIS method using anti-mouse IL-10 antibody (available from R & D) or anti-mouse TGF- ⁇ antibody (available from Promega), and the average value of 5 mice was determined.
- the results for Peyer's patch cells are shown in Table 3, and the results for intestinal lymph node cells are shown in Table 4.
- the percentage values in parentheses in the table are IgA, IgG, IFN-y, IL-4, IL-6, IL-10 or IL-10 produced in Peyer's patch cells or intestinal lymph node cells from which control mouse force was also collected.
- the relative value with respect to the amount of TGF ⁇ is shown.
- ratatosucrose increased the production of Peyer's patch cell IgA and IgG in a dose-dependent manner, and in addition, secreted IgA such as IL 6 and TGF- ⁇ . It also promoted the production of site power-in to promote. This result shows that ratatosucrose is applied to Peyer's patch cells. In contrast, it has an IgA secretion promoting effect.
- Table 4 in mesenteric lymph nodes, no increase in the production of IgA and various cytokines was observed. From the above, it is considered that ratatosucrose enhances the intestinal immunity function mainly due to the involvement of Peyer's patch cells.
- ratatosucrose was involved in systemic immunity was examined by measuring antibody serum levels.
- 6-week-old female BALBZc mice were preliminarily raised for 1 week on the standard purified feed (AIN-93G) used in Experiment 1, and then the lactated sugar containing a commercially available lactosucrose ( Combining the product name ⁇ Fruit Oligo 700 '', Hayashibara Shoji Co., Ltd., containing solid ratatosucrose 71.4% (wZw)), the ratatosucrose content is 2% (w / w) or 5%
- the test diet (w / w) mass content of ratatosucrose-containing saccharide, with reduced corn starch ability
- a mouse fed with a standard purified feed (AIN-93G) without ratatosucrose was prepared.
- Ten days after feeding the test feed 20 ⁇ g of ovalbumin (OVA) (sold by Sigma, Grade V) as an antigen and 4.5 mg of alum (registered trademark ⁇ ImjectJ, Pierce '') as an immune adjuvant were intraperitoneally injected.
- OVA ovalbumin
- alum registered trademark ⁇ ImjectJ, Pierce ''
- Ig Gl or IgG2a the amount of antibody in serum collected 2 weeks after the second antigen sensitization was measured.
- the IgE antibody titer and IgG2a antibody titer were measured by the capillary EIA method, and the IgGl antibody titer was measured by the indirect EIA method.
- Anti-OVA mouse blood ft (IgE: 1, 760U / ml, IgGl: 128, OOOU / ml, IgG2a: 7,040UZml) was used as the standard serum, and the antibody titer of each specimen was calculated using the prepared calibration curve. .
- Table 5 shows IgE levels 1, 2 or 3 weeks after the second antigen sensitization
- Table 6 shows IgGl or IgG2a levels 2 weeks after the second antigen sensitization.
- the percentage value in parentheses in the table represents the relative value for each antibody concentration in the serum of control mice.
- Cryj 1 (trade name “refined cedar pollen allergen Cryj 1”, sold by Seikagaku Corporation) was used in the same manner as in Experiment 4, except that 20 ⁇ g was administered.
- the amount of anti-Cryj 1-IgE was measured one week or two weeks after the second sensitization.
- anti-Cryj l-IgGl was measured 2 weeks after the second sensitization.
- the amount of anti-Cryj 1 —IgE and anti-Cryj 1—IgG1 were measured in the same manner as in Experiment 4 except that “purified cedar pollen antigen Cryj 1-Biotin” (sold by Seikagaku Corporation) was used as the solid phase.
- Table 7 shows the results for IgE V and Table 8 shows the results for IgG1!
- ratatosucrose suppressed the production of IFN- ⁇ , IL-2, IL-4 and IL-5 in splenocytes of mice sensitized with OVA. It was suggested that it has an action to suppress both Th2 and Th2. On the other hand, only the amount of IL10 slightly increased, although the production of other site power ins tended to be suppressed. This result indicates that ratatosucrose induces systemic immunity in a suppressive manner and that this immunosuppression involves regulatory T cells. From the above, ratatosucrose has an action of suppressing an excessive immune response in systemic immunity and can be advantageously used for the prevention or treatment of various allergic diseases and autoimmune diseases.
- ratatosucrose-containing starch syrup (trade name: “Fruit Oligo 700”, solid content: 76% (wZw)), Hayashibara Shoji Co., Ltd., converted to solids, 71.5% (wZw) Sucrose, 13.7% (wZw), latatoose 7.5% (w / w), and other sugars 7.3% (wZw)) in a container of aluminum pillow so that the ratatosucrose content is 3g. (Approx. 6 g of ratatosucrose-containing syrup) and handed over to the subjects assigned to the ratatosucrose intake group.
- sugar mixed isomerized liquid sugar (trade name “Corn Sugar A-33”, sold by Sanwa Starch Co., Ltd., solid content of about 75% (wZw), converted to solid, sucrose 33.5% (wZw) , Glucose 33.7% (wZw), fratatose 29.2% (wZw)), so that the solid content per container is the same as when sucrose containing sucrose outside ras is subdivided (sugar mixing) About 6 g of isomeric syrup sugar was given to the subjects assigned as the control intake group.
- the scoring of clinical symptoms taking into account the allergic symptom suppression effect of drugs is the total score of the clinical symptoms of the nose or eyes and the drug score It was.
- Nasal allergy clinical practice guideline preparation committee "nasal allergy clinical practice guideline-perennial rhinitis and hay fever-2005 edition", published by Life, Science, pages 24 to 27 (2006)), work
- the degree of hindrance in daily life such as studying, housework, sleeping and going out was scored according to the criteria shown in Table 16.
- the clinical symptoms of the nose and eyes and the score of the difficulty in daily life increased over time from the 4th week after the start of test substance intake.
- the floor symptom score peaked at 8 weeks after the start of test substance intake, dropped to 11 weeks, then remained at the same score until 15 weeks, and then further decreased.
- the ocular clinical symptom score peaked at 7 weeks after ingestion of the test substance.
- the score for the difficulty in daily life is the intake of the test substance. After peaking at week 8 and declining to week 12, it remained at the same score until week 15, and then declined further.
- the clinical nasal symptom score is not different between the sucrose intake group and the control intake group until 3 weeks after starting the test substance intake.
- the ratatosucrose intake group remained lower than the control intake group, and thereafter there was no difference between the two groups. Scores for ocular clinical symptoms and daily life disturbance remained lower in the ratatosucrose group than in the control group throughout the entire study period.
- each score of the subjects in this study is the start of cedar pollen scattering (test substance ingestion start 4 weeks), peak (test substance ingestion start 7 weeks), end (test substance ingestion start 11 weeks), cypress pollen scattering Since it is correlated with the start (test substance intake 11 weeks) and end (test substance intake 15 weeks), It was judged that it accurately reflected the relationship between the amount of cypress cypress pollen scattered, the degree of allergic symptoms, and the difficulty of daily life.
- Extra sucrose-containing carbohydrates (trade name “LS-90P”, sold by Shimizu Minato Sugar Co., Ltd., containing about 90% (wZw) ratatosucrose in terms of solids) 1 part by weight (X—Darcosyl stevioside (Product name “Hi-G-Sweet”, sold by Toyo Seika Co., Ltd.) 0. 05 parts by mass were mixed evenly and spread on a granulating machine to obtain a granular sweetener.
- X Darcosyl stevioside
- Hi-G-Sweet sold by Toyo Seika Co., Ltd.
- As a food it is suitable for sweetening low-calorie foods and drinks for obese and diabetics whose caloric intake is restricted, and by maintaining oral intake, the immune function can be adjusted, thus maintaining and improving health. It is also useful as a health food.
- Example 2 2 parts by weight of gum base is heated and melted to the extent that it softens, and then 2 parts by weight of maltose powder, 4 parts by weight of sucrose (sugar) powder and 1 part by weight of the sweetener obtained in Example 1 are added to the mixture.
- the chewing gum was obtained by mixing the scented fragrance and the colorant and kneading with a roll according to a conventional method and molding. This product is a chewing gum with a good flavor and can regulate immune function by ingestion, so it is useful as a health food that maintains and enhances health.
- Ratatosucrose-containing carbohydrate (trade name “LS-90P”, sold by Shimizu Minato Sugar Co., Ltd., containing approximately 90% ratatosucrose (w / w) in terms of solids)
- Ratatosucrose-containing carbohydrates (trade name “Milk Oligo 550”, sold by Hayashibara Shoji Co., Ltd., containing at least 55% ratatosucrose (w / w) in terms of solids)
- Glucose-transferred hesperidin (trade name “ ⁇ G Hesperidin”, sold by Hayashibara Shoji Co., Ltd.)
- Ratatosucrose-containing carbohydrates (trade name “Milk Oligo 700”, sold by Hayashibara Shoji Co., Ltd., containing approximately 70% ratatosucrose (w / w) in terms of solids)
- This product has a good flavor and regulates immune function when taken orally, so it is useful as a health food to maintain and improve health.
- the temperature was adjusted to 31 ° C with a temperature controller, poured into a mold just before the butter was solidified, and irrigated with a vibrator, and solidified by passing through a 10 ° C cooling tunnel for 20 minutes.
- This was die-cut and packaged to obtain chocolate.
- This product is a chocolate with hygroscopic color and gloss, good internal structure, smooth melting in the mouth, elegant sweetness and mellow flavor, and it can regulate immune function by ingestion, It is useful as a health food to maintain and improve health.
- a yogurt drink was prepared according to a conventional method, with a mixture of 0.25 parts by weight, yogurt flavor and 0.25 parts by weight of lemon essence and 0.1 parts by weight of water to add 1,000 parts by weight as a whole.
- This product is rich in flavor and yogurt with excellent intestinal function that adjusts the intestinal flora and can regulate immune function, so it is useful as a health food that maintains and improves health.
- Extra sucrose-containing saccharide powder (trade name “Walf Oligo LS-90P”, sold by Shimizu Minato Sugar Co., Ltd., containing about 90% ratatosucrose (wZw) in terms of solids) 70 parts by weight, erythritol 10 parts by weight , Royal Jelly Extract (Sold by Hayashibara Biochemical Laboratories, Inc., trade name “Hayashibara Royal Jelly X”) 20 parts by mass, Coenzyme Q 10 parts by mass, ascorbic acid 2—
- Dalcoside (Hayashibara Corporation, trade name “Asco Fresh”) 10 parts by weight, vitamin B 1 part by weight, vitamin B 1 part by weight, vitamin B 1 part by weight, orange powder 0.5 part by weight
- Mon essence 0.1 parts by mass was mixed, dried, sized, and packaged 2g each to produce a health food.
- This product is rich in flavor and has an excellent intestinal function that adjusts the intestinal flora, Moreover, since it can regulate the immune function, it is useful as a health food that maintains and enhances health.
- this product can be marketed as an immunomodulator because it has an immunomodulatory effect.
- Extra sucrose-containing saccharide powder (trade name “Fruit Oligo LS-90P”, sold by Shimizu Minato Sugar Co., Ltd., containing ratatosucrose 90% (wZw) in terms of solids) 50 parts by mass, rose petal extract 30 Part by weight, Royal Jelly Extract (Sold by Hayashibara Biochemical Laboratories Co., Ltd., trade name “Hayashibara Royal Jelly ⁇ ” 3 parts by weight, 3 parts by weight of yellow leaves extract, 3 parts by weight of tea extract, hydrous crystals OC, OC-trehalose (stock) 7 parts by weight, 3 parts by weight of emulsifier (sucrose fatty acid ester), 1 part by weight of crude seawater salt and magnesium, and after drying, size the mixture, 2g each
- This product is packaged to produce a health food that is rich in flavor, has an excellent intestinal function that regulates the flora in the intestines, and can regulate immune functions, thus maintaining and enhancing health.
- Ratatosucrose-containing saccharides (trade name “milk oligo 550”, sold by Hayashibara Shoji Co., Ltd., containing 55% (wZw) or more of ratatosucrose in terms of solids)
- the ratatosucrose-containing chicken feed was prepared by mixing the ratatosucrose content to 0.5% (w / w).
- the immunomodulating agent of the present invention has no side effects. It can prevent or treat infectious diseases such as food poisoning, allergic diseases, self-immune diseases, etc. because it can regulate immune function by daily oral intake. be able to. It also increases useful intestinal bacteria such as lactic acid bacteria and bifidobacteria and improves the intestinal environment, making it suitable for maintaining and promoting health.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/374,660 US20090270342A1 (en) | 2006-07-19 | 2007-07-06 | Immunoregulatory agent |
JP2008525832A JP5289952B2 (ja) | 2006-07-19 | 2007-07-06 | 免疫調節剤 |
EP07768313A EP2044945A4 (en) | 2006-07-19 | 2007-07-06 | IMMUNOMODULATING AGENT |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-197075 | 2006-07-19 | ||
JP2006197075 | 2006-07-19 | ||
JP2006-258120 | 2006-09-22 | ||
JP2006258120 | 2006-09-22 | ||
JP2007-146033 | 2007-05-31 | ||
JP2007146033 | 2007-05-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008010428A1 true WO2008010428A1 (fr) | 2008-01-24 |
Family
ID=38956762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/063582 WO2008010428A1 (fr) | 2006-07-19 | 2007-07-06 | Agent immunomodulateur |
Country Status (5)
Country | Link |
---|---|
US (1) | US20090270342A1 (ja) |
EP (1) | EP2044945A4 (ja) |
JP (1) | JP5289952B2 (ja) |
KR (1) | KR20090035682A (ja) |
WO (1) | WO2008010428A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727502A (zh) * | 2011-03-31 | 2012-10-17 | 盐水港精糖株式会社 | 抗流感病毒组合物及其饮食品、饲料及医药品 |
JP2013141438A (ja) * | 2012-01-11 | 2013-07-22 | Yakult Honsha Co Ltd | パフィアエキス含有飲料 |
JP2018183075A (ja) * | 2017-04-25 | 2018-11-22 | オリエンタル酵母工業株式会社 | 低蛍光性実験動物用飼料およびその製造方法 |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0327285A (ja) | 1989-06-26 | 1991-02-05 | Ensuiko Sugar Refining Co Ltd | 糖転移活性の強いβ―フラクトフラノシダーゼ、その製造法および該酵素を用いてアルドシルフラクトシドを製造する方法 |
JPH03290197A (ja) * | 1990-04-07 | 1991-12-19 | Hayashibara Biochem Lab Inc | ラクトスクロース含有粉末の製造方法とその粉末の用途 |
JPH04281795A (ja) * | 1990-03-08 | 1992-10-07 | Hayashibara Biochem Lab Inc | ラクトスクロース高含有粉末の製造方法とその粉末の用途 |
JPH10265390A (ja) * | 1997-03-27 | 1998-10-06 | Hayashibara Biochem Lab Inc | 腹部異常抑制用組成物 |
WO2002038146A1 (fr) | 2000-11-07 | 2002-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Immunomodulateur mucosal et son utilisation |
JP2002325555A (ja) | 2001-04-27 | 2002-11-12 | Takeda Food Products Ltd | 栄養障害による免疫機能低下を抑制する飲食品 |
JP2003040779A (ja) | 2001-07-27 | 2003-02-13 | Fancl Corp | 免疫調節剤 |
WO2004111067A1 (ja) * | 2003-06-10 | 2004-12-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α−グリコシルα,α−トレハロースと金属イオン化合物との会合物 |
WO2005039597A2 (en) * | 2003-10-24 | 2005-05-06 | N.V. Nutricia | Immunemodulating oligosaccharides |
JP2005211077A (ja) * | 2005-03-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | β−マルトース含水結晶含有粉末とその製造方法並びに用途 |
WO2006011301A1 (ja) * | 2004-07-29 | 2006-02-02 | Ensuiko Sugar Refining Co., Ltd. | 結晶ラクトスクロースまたはそれを含有する含蜜結晶とその用途 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69312851T2 (de) * | 1992-04-10 | 1998-01-08 | Otsuka Pharma Co Ltd | Nahrungsmittelzusammensetzung zur hemmung von der bildung von darmverrottungsprodukten |
JP2789069B2 (ja) * | 1992-04-10 | 1998-08-20 | 大塚製薬株式会社 | 腸内腐敗産物生成抑制飲料組成物 |
JPH11124390A (ja) * | 1997-10-22 | 1999-05-11 | Otsuka Pharmaceut Co Ltd | 皮膚疾患治療組成物 |
JP2001064181A (ja) * | 1999-08-27 | 2001-03-13 | Otsuka Pharmaceut Co Ltd | 免疫賦活組成物 |
US6897202B2 (en) * | 2001-08-22 | 2005-05-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Powder comprising water-containing β-maltose crystals and production process and use thereof |
JP2003334030A (ja) * | 2002-05-22 | 2003-11-25 | Toyo Shinyaku:Kk | 健康食品 |
JP4452569B2 (ja) * | 2004-06-29 | 2010-04-21 | 有限会社フードデザイン健康研究所 | 桃の花及びラクトフェリンを主成分とする食品 |
JP2006149371A (ja) * | 2004-08-24 | 2006-06-15 | Asama Chemical Co Ltd | 乳清タンパク食品 |
WO2006035979A1 (ja) * | 2004-09-29 | 2006-04-06 | Asama Chemical Co., Ltd. | 乳清タンパク、乳由来の抗体または抗体を含む機能性組成物または食品 |
-
2007
- 2007-07-06 KR KR1020097001046A patent/KR20090035682A/ko not_active Application Discontinuation
- 2007-07-06 WO PCT/JP2007/063582 patent/WO2008010428A1/ja active Application Filing
- 2007-07-06 EP EP07768313A patent/EP2044945A4/en not_active Withdrawn
- 2007-07-06 US US12/374,660 patent/US20090270342A1/en not_active Abandoned
- 2007-07-06 JP JP2008525832A patent/JP5289952B2/ja active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0327285A (ja) | 1989-06-26 | 1991-02-05 | Ensuiko Sugar Refining Co Ltd | 糖転移活性の強いβ―フラクトフラノシダーゼ、その製造法および該酵素を用いてアルドシルフラクトシドを製造する方法 |
JPH04281795A (ja) * | 1990-03-08 | 1992-10-07 | Hayashibara Biochem Lab Inc | ラクトスクロース高含有粉末の製造方法とその粉末の用途 |
JPH03290197A (ja) * | 1990-04-07 | 1991-12-19 | Hayashibara Biochem Lab Inc | ラクトスクロース含有粉末の製造方法とその粉末の用途 |
JPH10265390A (ja) * | 1997-03-27 | 1998-10-06 | Hayashibara Biochem Lab Inc | 腹部異常抑制用組成物 |
WO2002038146A1 (fr) | 2000-11-07 | 2002-05-16 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Immunomodulateur mucosal et son utilisation |
JP2002325555A (ja) | 2001-04-27 | 2002-11-12 | Takeda Food Products Ltd | 栄養障害による免疫機能低下を抑制する飲食品 |
JP2003040779A (ja) | 2001-07-27 | 2003-02-13 | Fancl Corp | 免疫調節剤 |
WO2004111067A1 (ja) * | 2003-06-10 | 2004-12-23 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | α−グリコシルα,α−トレハロースと金属イオン化合物との会合物 |
WO2005039597A2 (en) * | 2003-10-24 | 2005-05-06 | N.V. Nutricia | Immunemodulating oligosaccharides |
WO2006011301A1 (ja) * | 2004-07-29 | 2006-02-02 | Ensuiko Sugar Refining Co., Ltd. | 結晶ラクトスクロースまたはそれを含有する含蜜結晶とその用途 |
JP2005211077A (ja) * | 2005-03-30 | 2005-08-11 | Hayashibara Biochem Lab Inc | β−マルトース含水結晶含有粉末とその製造方法並びに用途 |
Non-Patent Citations (6)
Title |
---|
"HANA ALLERGY SHINDAN GUIDELINE -TUNENsEI BIEN TO KAFUNSHO- 2005 NENDO-BAN", 2006, LIFE SCIENCE, article "Guideline for the diagnosis of nose allergy -chronic allergic rhinitis and pollinosis- 2005 edition", pages: 20 - 24 |
"HANA ALLERGY SHINDAN GUIDELINE -TUNENSEI BIEN TO KAFUNSHO- 2005 NENDO-BAN", 2006, LIFE SCIENCE, article "Guideline for the diagnosis of nose allergy -chronic allergic rhinitis and pollinosis 2005 edition", pages: 20 - 24 |
"HANA ALLERGY SHINDAN GUIDELINE -TUNENSEI BIEN TO KAFUNSHO- 2005 NENDO-BAN", 2006, LIFE SCIENCE, article "Guideline for the diagnosis of nose allergy -chronic allergic rhinitis and pollinosis 2005 edition", pages: 24 - 27 |
K. OHKUBO ET AL., ALLERGY NO RYOIKI (SECTION OF ALLERGY, vol. 5, no. 11, 1998, pages 1491 - 1499 |
See also references of EP2044945A4 * |
Y. ISHIDA, BIOSCI. BIOTECNOL. BIOCHEM., vol. 69, no. 9, 2005, pages 1652 - 1660 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102727502A (zh) * | 2011-03-31 | 2012-10-17 | 盐水港精糖株式会社 | 抗流感病毒组合物及其饮食品、饲料及医药品 |
JP2012214403A (ja) * | 2011-03-31 | 2012-11-08 | Ensuiko Sugar Refining Co Ltd | 抗インフルエンザウイルス用組成物 |
CN102727502B (zh) * | 2011-03-31 | 2016-03-09 | 盐水港精糖株式会社 | 抗流感病毒组合物及其饮食品、饲料及医药品 |
JP2013141438A (ja) * | 2012-01-11 | 2013-07-22 | Yakult Honsha Co Ltd | パフィアエキス含有飲料 |
JP2018183075A (ja) * | 2017-04-25 | 2018-11-22 | オリエンタル酵母工業株式会社 | 低蛍光性実験動物用飼料およびその製造方法 |
Also Published As
Publication number | Publication date |
---|---|
US20090270342A1 (en) | 2009-10-29 |
JPWO2008010428A1 (ja) | 2009-12-17 |
EP2044945A1 (en) | 2009-04-08 |
EP2044945A4 (en) | 2012-05-30 |
KR20090035682A (ko) | 2009-04-10 |
JP5289952B2 (ja) | 2013-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2368333T3 (es) | Métodos de uso de bifidobacterias probióticas para animales de compañia. | |
CA2782052C (en) | Methods of use of probiotic lactobacilli for companion animals | |
JP4667568B2 (ja) | 免疫増強組成物 | |
JP5191955B2 (ja) | 粘膜免疫調節剤並びにその用途 | |
JP2008535520A (ja) | プロバイオティクス構成成分及び甘味剤構成成分を含む組成物 | |
BRPI0417826B1 (pt) | composição compreendendo uma cepa bifidobactéria pseudolongum probiótica canina | |
EP2386311A1 (en) | Compositions for improving lipid metabolism | |
US20040044079A1 (en) | Methods and compositions for weight control | |
JP5289952B2 (ja) | 免疫調節剤 | |
AU777971B2 (en) | Methods and compositions for modulating immune response and for the treatment of inflammatory disease | |
JP6742981B2 (ja) | 免疫調節剤及びその用途 | |
US20180147235A1 (en) | Allergy vaccine composition | |
JP2003113089A (ja) | 脂質蓄積性阻害およびコレステロール低下作用を有するキトサン含有製剤および飲食品 | |
JP2009143851A (ja) | LPS誘導IgM産生増強剤 | |
JP2008195713A (ja) | 免疫調節剤 | |
JP7260113B2 (ja) | 徐波活動促進剤 | |
JPH0912466A (ja) | 脂質の吸収阻害・排出促進剤および高脂肪食品 | |
WO2019146652A1 (ja) | 抗i型アレルギー剤、及び肥満細胞又は好塩基球の脱顆粒抑制剤、並びに抗認知症剤、及び短期記憶障害改善/抑制剤 | |
JPWO2020040216A1 (ja) | 深部体温低下剤 | |
WO2020004463A1 (ja) | 糖尿病性末梢神経障害の予防又は治療用組成物 | |
JP2000204044A (ja) | 便通、便の性状及び便臭改善剤、経腸栄養食品、便臭改善効果を有する飲食品及び飼料 | |
JPH10265398A (ja) | 血中脂質改善剤および血中脂質改善作用を有する飲食品 | |
WO2007034748A1 (ja) | 腸管免疫調節剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07768313 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2008525832 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020097001046 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12374660 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007768313 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |